192 related articles for article (PubMed ID: 29981260)
1. Gut-liver on a chip toward an in vitro model of hepatic steatosis.
Lee SY; Sung JH
Biotechnol Bioeng; 2018 Nov; 115(11):2817-2827. PubMed ID: 29981260
[TBL] [Abstract][Full Text] [Related]
2. In vitro hepatic steatosis model based on gut-liver-on-a-chip.
Jeon JW; Lee SH; Kim D; Sung JH
Biotechnol Prog; 2021 May; 37(3):e3121. PubMed ID: 33393209
[TBL] [Abstract][Full Text] [Related]
3. A body-on-a-chip (BOC) system for studying gut-liver interaction.
Sung JH
Methods Cell Biol; 2020; 158():1-10. PubMed ID: 32423644
[TBL] [Abstract][Full Text] [Related]
4. Microfluidic Gut-liver chip for reproducing the first pass metabolism.
Choe A; Ha SK; Choi I; Choi N; Sung JH
Biomed Microdevices; 2017 Mar; 19(1):4. PubMed ID: 28074384
[TBL] [Abstract][Full Text] [Related]
5. Investigating Nonalcoholic Fatty Liver Disease in a Liver-on-a-Chip Microfluidic Device.
Gori M; Simonelli MC; Giannitelli SM; Businaro L; Trombetta M; Rainer A
PLoS One; 2016; 11(7):e0159729. PubMed ID: 27438262
[TBL] [Abstract][Full Text] [Related]
6. 3D gut-liver chip with a PK model for prediction of first-pass metabolism.
Lee DW; Ha SK; Choi I; Sung JH
Biomed Microdevices; 2017 Nov; 19(4):100. PubMed ID: 29116458
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B Virus X Protein Induces Hepatic Steatosis by Enhancing the Expression of Liver Fatty Acid Binding Protein.
Wu YL; Peng XE; Zhu YB; Yan XL; Chen WN; Lin X
J Virol; 2016 Feb; 90(4):1729-40. PubMed ID: 26637457
[TBL] [Abstract][Full Text] [Related]
8. Barley sprout extracts reduce hepatic lipid accumulation in ethanol-fed mice by activating hepatic AMP-activated protein kinase.
Kim YJ; Hwang SH; Jia Y; Seo WD; Lee SJ
Food Res Int; 2017 Nov; 101():209-217. PubMed ID: 28941686
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
[TBL] [Abstract][Full Text] [Related]
10. Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways.
Pachikian BD; Essaghir A; Demoulin JB; Catry E; Neyrinck AM; Dewulf EM; Sohet FM; Portois L; Clerbaux LA; Carpentier YA; Possemiers S; Bommer GT; Cani PD; Delzenne NM
Mol Nutr Food Res; 2013 Feb; 57(2):347-59. PubMed ID: 23203768
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
[TBL] [Abstract][Full Text] [Related]
12. Lipoic Acid Prevents High-Fat Diet-Induced Hepatic Steatosis in Goto Kakizaki Rats by Reducing Oxidative Stress Through Nrf2 Activation.
Sena CM; Cipriano MA; Botelho MF; Seiça RM
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208622
[TBL] [Abstract][Full Text] [Related]
13. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
14. An on-chip small intestine-liver model for pharmacokinetic studies.
Kimura H; Ikeda T; Nakayama H; Sakai Y; Fujii T
J Lab Autom; 2015 Jun; 20(3):265-73. PubMed ID: 25385717
[TBL] [Abstract][Full Text] [Related]
15. Integrated-gut-liver-on-a-chip platform as an in vitro human model of non-alcoholic fatty liver disease.
Yang J; Hirai Y; Iida K; Ito S; Trumm M; Terada S; Sakai R; Tsuchiya T; Tabata O; Kamei KI
Commun Biol; 2023 Mar; 6(1):310. PubMed ID: 36959276
[TBL] [Abstract][Full Text] [Related]
16. Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging.
Kim SM; Lee B; An HJ; Kim DH; Park KC; Noh SG; Chung KW; Lee EK; Kim KM; Kim DH; Kim SJ; Chun P; Lee HJ; Moon HR; Chung HY
Oncotarget; 2017 Jul; 8(28):46273-46285. PubMed ID: 28545035
[TBL] [Abstract][Full Text] [Related]
17. Quercetin and hydroxytyrosol as modulators of hepatic steatosis: A NAFLD-on-a-chip study.
Gori M; Giannitelli SM; Zancla A; Mozetic P; Trombetta M; Merendino N; Rainer A
Biotechnol Bioeng; 2021 Jan; 118(1):142-152. PubMed ID: 32889748
[TBL] [Abstract][Full Text] [Related]
18. Endogenous formation of Nε-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis.
Gaens KH; Niessen PM; Rensen SS; Buurman WA; Greve JW; Driessen A; Wolfs MG; Hofker MH; Bloemen JG; Dejong CH; Stehouwer CD; Schalkwijk CG
J Hepatol; 2012 Mar; 56(3):647-55. PubMed ID: 21907687
[TBL] [Abstract][Full Text] [Related]
19. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
Lee MR; Yang HJ; Park KI; Ma JY
Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
